With three FDA clearances and two CE marks, UltraSightHD is a trusted AI-assisted solution designed to expand access to early detection globally.
Introduction to UltraSightHD Video
As global shortages of gynecologists and pathologists continue to strain healthcare systems, UltraSightHD provides a scalable AI-powered solution that expands screening access, increases clinical efficiency, and supports earlier cervical cancer detection.
Millions of women lack timely access to cervical cancer screening due to limited clinic infrastructure, and qualified medical specialist.
A growing global shortage of gynecologists, cytotechnologists, and pathologists is limiting access to timely cervical cancer screening and diagnosis.
WHO initiatives are accelerating demand for screening technologies. Hundreds of thousands of women die annually despite the disease being highly preventable.
ImageSense AI analyzes acetowhite patterns in real-time, instantly identifying lesions, pinpointing their location, and assessing their severity — giving every clinician the expertise of a specialist.
Every image is calibrated, in-focus, and archive-grade. This consistency means a colposcopist can compare exam-to-exam and location-to-location with full confidence — regardless of operator or setting.
It enables real-time remote diagnosis, allowing experts to provide care globally with immediate results. For the first time the doctor comes to the patient.
Continuously growing cervical imaging database powering future AI advancement.
The UltraSightHD platform is building the world's first AI-powered cervical cancer screening infrastructure — a platform that generates recurring reimbursement revenue while eliminating a disease that kills 340,000 women annually